Moreover, a shorter GILZ protein sequence-derived peptide was shown to be effective in suppressing neuroinflammation in the mouse model of induced multiple sclerosis, demonstrating the feasibility of the experimental approach of using GILZ-based peptide as a pharmacologic tool in an in vivo model of multiple sclerosis [52]. Here, TSC22D3 is linked to multiple sclerosis.